We observed no interaction between 3 SNPS in CYP2E1 and acrylamide intake for ER+ breast cancer risk and there were no clear differences in the risk between the genotypes, contrary to what was observed for endometrial [7] and ovarian cancer [8]. The gene discussed is CYP2E1; the disease is ovarian cancer.